A practical method for measuring planar spatial resolution with scatter on a CZT gamma camera.

PURPOSE: This study proposes a practical method for evaluating 2D spatial resolution with scatter on a CZT planar detector gamma camera, which is simpler and faster than the NEMA method. It is used to characterize the influence of distance on spatial resolution FWHM on a CZT camera equipped with a WEHR collimator. METHODS: The practical method uses linear sources tilted with respect to the detector axes. The spatial resolution full width at half maximum (FWHM) with four tilt angles was compared to the FWHM evaluated using the NEMA NU1-2018 method. Spatial resolution FWHM was also assessed with tilted sources acquired at distances of 0 to 20 cm using a single angle, with and without the post-processing image enhancement proposed by the manufacturer. RESULTS: Estimated spatial resolution FWHM with tilted sources was close to the spatial resolution FWHM estimated at 7.63 mm by the NEMA method, with deviations ranging from - 5.62 to 4.59% at 10 cm depending on the angle considered. The study of spatial resolution FWHM dependence on distance indicates that, for distances less than 3 cm, the FWHM no longer decreases with distance. The manufacturer's post-processing reduces the FWHM by an average of 15%. CONCLUSION: The practical method is quicker to implement and gives comparable results to the NEMA reference method for spatial resolution FWHM. Evaluation of spatial resolution with linear sources at short distances from the collimator is limited by the collimator effect and signal digitization. The tilted source method can be used to measure spatial resolution quickly and easily under clinical conditions for CZT planar cameras.

Dosimetric Considerations for 177 Lu-DOTATATE Therapy in a Patient With Chronic Renal Failure Under Hemodialysis.

ABSTRACT: This case report explores the use of 177 Lu-DOTATATE in a hemodialysis patient. For the first time, this study assesses the average dose received by the bone marrow, the primary organ at risk, using an original double estimation method through independently acquired imaging and biological samples counting data. Despite elevated doses, the absorbed doses to the bone marrow (0.662-0.740 Gy) were within safe limits. Radiation protection measurements for staff were also compliant. This work supports that effective early dialysis and systematic personalized dosimetry are crucial for hemodialysis patients undergoing 177 Lu-PRRT due to their variability (residual excretion, treatment history, etc).

Estimated Fetal Radiation Dose From 18 F-FDG PET/CT During the Second and Third Trimesters of Pregnancy.

PURPOSE: Data published in the literature concerning the doses received by fetuses exposed to a 18 F-FDG PET are reassuring but were obtained from small and heterogeneous cohorts, and very few data are available concerning the fetal dose received after exposure to both PET and CT. The present study aimed to estimate the fetal dose received following a PET/CT exposure using methods that include anthropomorphic phantoms of pregnant women applied on a large cohort. PATIENTS AND METHODS: This retrospective multicenter study included 18 pregnant patients in the second and third trimesters. For PET exposure, the fetal volume and mean concentration of radioactivity in the fetus were measured by manually drawing regions of interest. Those data, combined with the time-integrated activities of the fetus and the mother's organs, were entered into the OLINDA/EXM software 2.0 to assess the fetal dose due to PET exposure. To estimate the fetal dose received due to CT exposure, 2 softwares were used: CT-Expo (based on geometric phantom models of nonpregnant patients) and VirtualDose (using pregnant patient phantoms). RESULTS: The fetal dose exposure for PET/CT examination in the second trimester ranged from 5.7 to 15.8 mGy using CT-Expo (mean, 11.6 mGy) and from 5.1 to 11.6 mGy using VirtualDose (mean, 8.6 mGy). In the third trimester, it ranged from 7.9 to 16.6 mGy using CT-Expo (mean, 10.7 mGy) and from 6.1 to 10.7 mGy using VirtualDose (mean, 7.6 mGy). CONCLUSIONS: The estimated fetal doses were in the same range of those previously published and are well below the threshold for deterministic effects. Pregnancy does not constitute an absolute contraindication for a clinically justified hybrid 18 F-FDG PET/CT.

Tissue dose estimation after extravasation of 177Lu-DOTATATE.

BACKGROUND: Extravasation of radiopharmaceuticals used for vectorized internal radiotherapy can lead to severe tissue damage (van der Pol et al., Eur J Nucl Med Mol Imaging 44:1234-1243, 2017). Clinical management of these extravasations requires the preliminary estimation of the dose distribution in the extravasation area. Data are scarce regarding the dose estimation in the literature. This work presents a methodology for estimating the dose distribution after an extravasation occurred in September 2017, in the arm of a patient during a 7.4-GBq infusion of Lutathera ® (AAA). METHODS: A local quantification procedure initially developed for renal dosimetry was used. A calibration factor was determined and verified by phantom study. Extravasation volume of interest and its variation in time were determined using 4 whole body (WB) planar acquisitions performed at 2 h (T2h), 5 h (T5h), 20 h (T20h), and 26 h (T26h) after the beginning of the infusion and three SPECT/CT thoracic acquisitions at T5h, T20h, and T26h. For better estimation of initial extravasation volume, 3 volumes were defined on SPECT images using a 3D activity threshold. Cumulated activities and associated absorbed doses (D1, D2, D3) were calculated in the 3 volumes using the MIRD formalism. RESULTS: Volumes estimated using 3D threshold were V1 = 1000 mL, V2 =400 mL, and V3 =180 mL. Cumulated activities were evaluated using a monoexponential fit on activities calculated on SPECT images. Estimated local absorbed doses in V1, V2, and V3 were D1 = 2.3 Gy, D2 = 4.1 Gy, and D3 = 6.8 Gy. Evolution in time of local activity in the extravasation area was consistent with an effective local half-life (Teff) of 2.3 h. CONCLUSIONS: Rapid local dose estimation was permitted thanks to knowledge of the calibration factor determined previous to accidental extravasation. Lutathera® lymphatic drainage was quick in the arm (Teff = 2.3h). Estimated doses were in the lower range of deterministic effects and far under soft tissue necrosis threshold. Thus, no surgical rinse was proposed. The patient did not show any clinical consequence of the extravasation.

Reduced Scan Time in 123I-FP-CIT SPECT Imaging Using a Large-Field Cadmium-Zinc-Telluride Camera.

We evaluated the reproducibility of I-ioflupane (I-FP-CIT) SPECT with shorter scan times using a CZT camera. One hundred ninety-nine I-FP-CIT SPECT scans obtained with standard scan time (30 minutes) were truncated to provide 24-, 18-, and 15-minute study simulations. Striatal binding ratios were automatically calculated and remained stable for all series. At 15 minutes, only 10 of 398 striata (2.5%) showed statistically significant different striatal binding ratios compared with reference series. These series were reviewed by 2 operators, and a perfect agreement was found for each patient. Therefore, CZT camera allows a 2-fold scan time reduction in I-FP-CIT SPECT.

Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT.

PURPOSE: Our aims were to assess the feasibility of imaging hypoxia in cervical carcinoma with (18)F-fluoroerythronitroimidazole ((18)F-FETNIM) and to compare (18)F-FETNIM uptake with metabolic uptake of (18)F-FDG. PATIENTS AND METHODS: We included 16 patients with cervical carcinoma. After imaging with FDG, (18)F-FETNIM PET/CT was performed and tumor-to-muscle (T/M) ratio uptake was assessed. (18)F- FETNIM uptake was correlated to FDG uptake and osteopontin (OPN), a marker of hypoxia, and patients' outcomes. RESULTS: All tumors were detected by (18)F-FDG PET. (18)F-FETNIM T/M ratios ranged from 1.3 to 5.4. There was no significant correlation between (18)F-FETNIM and (18)F-FDG uptake. High (18)F-FETNIM uptake (T/M > 3.2) was associated with reduced progression-free survival (log-rank = 0.002) and overall survival (log-rank = 0.02). Osteopontin ranged from 39 to 662 µg/L (median, 102.5 µg/L). Patients with OPN greater than 144 µg/L had reduced progression-free survival compared with those with OPN less than 144 µg/L (log-rank = 0.03). We found no significant correlation between (18)F-FETNIM uptake and OPN blood levels. CONCLUSIONS: Our preliminary results showed that a high uptake of (18)F-FETNIM was associated with a worse progression-free and overall survival.

Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET.

UNLABELLED: In (18)F-FDG PET, tumors are often characterized by their metabolically active volume and standardized uptake value (SUV). However, many approaches have been proposed to estimate tumor volume and SUV from (18)F-FDG PET images, none of them being widely agreed upon. We assessed the accuracy and robustness of 5 methods for tumor volume estimates and of 10 methods for SUV estimates in a large variety of configurations. METHODS: PET acquisitions of an anthropomorphic phantom containing 17 spheres (volumes between 0.43 and 97 mL, sphere-to-surrounding-activity concentration ratios between 2 and 68) were used. Forty-one nonspheric tumors (volumes between 0.6 and 92 mL, SUV of 2, 4, and 8) were also simulated and inserted in a real patient (18)F-FDG PET scan. Four threshold-based methods (including one, T(bgd), accounting for background activity) and a model-based method (Fit) described in the literature were used for tumor volume measurements. The mean SUV in the resulting volumes were calculated, without and with partial-volume effect (PVE) correction, as well as the maximum SUV (SUV(max)). The parameters involved in the tumor segmentation and SUV estimation methods were optimized using 3 approaches, corresponding to getting the best of each method or testing each method in more realistic situations in which the parameters cannot be perfectly optimized. RESULTS: In the phantom and simulated data, the T(bgd) and Fit methods yielded the most accurate volume estimates, with mean errors of 2% +/- 11% and -8% +/- 21% in the most realistic situations. Considering the simulated data, all SUV not corrected for PVE had a mean bias between -31% and -46%, much larger than the bias observed with SUV(max) (-11% +/- 23%) or with the PVE-corrected SUV based on T(bgd) and Fit (-2% +/- 10% and 3% +/- 24%). CONCLUSION: The method used to estimate tumor volume and SUV greatly affects the reliability of the estimates. The T(bgd) and Fit methods yielded low errors in volume estimates in a broad range of situations. The PVE-corrected SUV based on T(bgd) and Fit were more accurate and reproducible than SUV(max).